Press Releases
Stay Informed with the Latest Updates from EpiMedTech Global
Discover the cutting-edge advancements and impactful collaborations that drive our mission to revolutionize healthcare through epigenetics. Explore our latest press releases and stay up-to-date with our journey toward transforming global health.
![](https://epimedtech.com/wp-content/uploads/2024/01/Interview-How-CluePoints-is-making-clinical-trials-safer-streamlined-and-more-efficient.jpg)
![](https://epimedtech.com/wp-content/uploads/2024/08/NIBA-300x173.png)
EpiMedTech Global to Present at the 150th National Investment Banking Association Conference Slated for September 4-5 in Ft. Lauderdale
Singapore – News File Corp. – August 27, 2024 – EpiMedTech Global, a company focused on revolutionizing healthcare through real-world applications for early disease detection, today announced that the company
![](https://epimedtech.com/wp-content/uploads/2024/08/Moshe_NIBA-300x300.jpeg)
EpiMedTech Global Featured in Coverage of NIBA’s 150th Investment Conference
EpiMedTech Global Featured in Coverage of NIBA’s 150th Investment Conference EpiMedTech Global, a pioneering company dedicated to transforming healthcare through the power of epigenetics, has been featured in the coverage
![](https://epimedtech.com/wp-content/uploads/2023/06/CLIA-2023-25-300x196.png)
HKG Epitherapeutics Ltd. Secures CLIA Registration Certificate, A Significant Step Forward in Clinical Laboratory Services
HKG Epitherapeutics Ltd receives CLIA certification, a testament to its dedication to excellence in clinical laboratory testing. Discover the impact of this achievement on the company’s growth and contribution to healthcare innovation.
![](https://epimedtech.com/wp-content/uploads/2023/06/EpiLiver-press-release-300x240.jpg)
Pioneering High-Throughput Assay for Swift Detect of Liver Cancer Unveiled by HKG Epitherapeutics Ltd and Collaborat
Discover the groundbreaking high-throughput test developed by HKG Epitherapeutics and partners for the early detection of Hepatocellular Carcinoma. Utilizing distinctive DNA methylation signatures, this revolutionary assay holds the promise of transforming liver cancer detection and saving lives.
![](https://epimedtech.com/wp-content/uploads/2023/12/HKG_LOGO-300x158.png)
HKG EPITHERAPEUTICS LTD Laboratory RECEIVES ACCREDITATION FROM COLLEGE OF AMERICAN PATHOLOGISTS
Hong Kong, January 12, 2022 The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to HKG epiTherapeutics Ltd Laboratory, Hong Kong, based on results of
![](https://epimedtech.com/wp-content/uploads/2023/12/HKG_LOGO-300x158.png)
HIPAA Press Release
HKG Epitherapeutics is pleased to announce that it has achieved compliance with the federally mandated standards of the Health Insurance Portability and Accountability Act (HIPAA) through the use of Compliancy